Indegene Share Price Target 2026 Analyst Forecast Bull and Bear Case

The Indegene share price target 2026 is Rs 610, based on analyst estimates and the FY27 earnings recovery thesis for Indegene (NSE: INDGN). Q4 FY26 results released in 2026 are the immediate re-rating trigger. This article covers the complete Indegene share price target analysis including sector tailwinds, peer context, key risks, and bull and bear case scenarios.

Click Here – Get Free Investment Predictions

Indegene Share Price Target 2026: Key Takeaways

• Indegene share price target 2026: Rs 610 (20% upside from CMP Rs 510.35)
• Bull case: Rs 740 | Bear case: Rs 410
• Ticker: INDGN | Sector: Healthcare Technology and Life Sciences Services | MCap: Rs 12,756 crore
• 52W range: Rs 420 to Rs 800 | PE: 45x
• Key catalyst: Q4 FY26 results released in 2026 confirming FY27 earnings trajectory
• Key risk: FY27 earnings miss or sustained FII outflows from Indian equities

Indegene Company Overview

Indegene (NSE: INDGN) is a Bengaluru-based healthcare technology company providing digital and data-driven services to global life sciences, pharmaceutical, and medical device companies, listed in 2024, with FY26 revenue growing 25 percent year-on-year from expanding US pharma commercialisation mandates. At CMP Rs 510.35 against a 52 week range of Rs 420 to Rs 800, the stock trades at a discount to its 52 week high. Market capitalisation is Rs 12,756 crore with trailing PE of 45x. Compared to peers in healthcare IT like Syneos Health and IQVIA, Indegene is positioned as a potential re-rating candidate toward the Indegene share price target of Rs 610.

Parameter	Value
NSE Ticker	INDGN
Sector	Healthcare Technology and Life Sciences Services
CMP (2026)	Rs 510.35
52 Week High	Rs 800
52 Week Low	Rs 420
Market Cap	Rs 12,756 crore
Trailing PE	45x
12-Month Analyst Target	Rs 610
Bull Case Target	Rs 740
Bear Case Target	Rs 410

Why Is the Indegene Share Price Target Set at Rs 610 for 2026

FY27 Earnings Delivery and Revenue Acceleration

The Indegene share price target 2026 of Rs 610 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings recovery trajectory are the most direct catalyst for re-rating from CMP Rs 510.35 toward Rs 610.

Structural Sector Tailwinds in Healthcare Technology and Life Sciences Services

The Healthcare Technology and Life Sciences Services sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising investment. Indegene’s market position among peers in healthcare IT like Syneos Health and IQVIA creates a structural growth runway supporting the Indegene share price target of Rs 610 and bull case of Rs 740.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s RBI rate cut cycle in 2026 reduces Indegene’s borrowing costs and stimulates end market demand. Lower interest costs improve the EPS trajectory, directly supporting the Indegene share price target of Rs 610.

Union Budget 2026-27 Policy Support

Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a positive policy backdrop for Indegene’s Healthcare Technology and Life Sciences Services operations, improving the probability of achieving the Indegene share price target of Rs 610.

Improving FII Flows and Market Normalisation in 2026

As global macro conditions normalise through 2026, FII flows into quality Indian equities are recovering. At 45x PE, Indegene is positioned as a beneficiary of institutional reallocation toward the Indegene share price target of Rs 610.

Indegene Share Price Targets: Short Term, 12 Month, and Long Term

Short Term Indegene Share Price Target

The near-term Indegene share price target is anchored to support near the 52 week low of Rs 420. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating toward Rs 610.

12-Month Indegene Share Price Target 2026

The 12-month Indegene share price target 2026 is Rs 610, implying approximately 20 percent upside from CMP Rs 510.35. This base case assumes in-line FY27 earnings delivery and partial FII flow normalisation. Track live on NSE ticker INDGN.

Long Term Indegene Share Price Target: FY27 to FY28

For investors with a 2 to 3 year horizon, the long-term Indegene share price target is Rs 740 in the bull case, assuming full earnings delivery and sector re-rating among peers in healthcare IT like Syneos Health and IQVIA.

Bull Case and Bear Case for the Indegene Share Price Target

Bull Case Indegene Share Price Target: Rs 740

The bull case of Rs 740 materialises when FY27 earnings beat analyst estimates, Healthcare Technology and Life Sciences Services tailwinds accelerate, and FII flows return strongly, enabling re-rating toward higher peer multiples in 2026 and beyond.

Bear Case Indegene Share Price Target: Rs 410

The bear case of Rs 410 materialises if FY27 earnings disappoint and FII outflows persist, with the stock approaching the 52 week low support of Rs 420.

Scenario	Target	Key Conditions
Bull Case	Rs 740	FY27 earnings beat, re-rating, FII inflows
Base Case	Rs 610	In-line FY27 delivery, partial FII recovery
Bear Case	Rs 410	FY27 miss, guidance cut, FII outflows

Key Risks to the Indegene Share Price Target 2026

Global Macro and Tariff Risk

Global tariff tensions and macro headwinds remain a key risk to the Indegene share price target 2026 of Rs 610, with FII outflows a direct consequence of sustained geopolitical uncertainty.

Valuation and Earnings Miss Risk

Any FY27 earnings miss or guidance cut could compress multiples, posing the most direct risk to the Indegene share price target of Rs 610.

Competitive Pressure in Healthcare Technology and Life Sciences Services

Intensifying competition among peers in healthcare IT like Syneos Health and IQVIA could compress Indegene’s pricing power, a structural risk that must be factored into any assessment of the Indegene share price target of Rs 610.

FII Selling and Liquidity Risk

Sustained FII outflows from Indian equities can delay re-rating toward the Indegene share price target of Rs 610 regardless of company-level improvement through FY27.

How to Invest in Indegene

Check the Univest Screener for live data

Begin by reviewing Indegene’s Q4 FY26 results, annual report, and FY27 guidance released in 2026 before forming a view on the Indegene share price target of Rs 610. Focus on revenue growth, margin trends, and management commentary on Healthcare Technology and Life Sciences Services sector opportunities.

Open a Demat and trading account with a SEBI registered stockbroker to buy Indegene (NSE: INDGN) with full regulatory protection. Understand the competitive dynamics among peers in healthcare IT like Syneos Health and IQVIA before executing any position.

Plan your entry near the 52 week low support of Rs 420. A confirmed FY27 earnings uptick would strengthen the entry case for the Indegene share price target of Rs 610. Set a disciplined stop loss below the 52 week low.

Restrict any single stock to 3 to 5 percent of your total equity portfolio to manage concentration risk, especially in the Healthcare Technology and Life Sciences Services space where sectoral cycles can amplify volatility.

Always consult a SEBI registered financial advisor before investing based on any Indegene share price target estimate. SEBI Registration No. INH000013776.

Download the Univest iOS App or the Univest Android App to track Indegene’s live price and get daily stock recommendations.

FAQs on Indegene Share Price Target 2026

What is the Indegene share price target for 2026?

Ans. The Indegene share price target 2026 is Rs 610, implying approximately 20 percent upside from CMP Rs 510.35. Bull case is Rs 740 and bear case is Rs 410.

What is the Indegene share price target for 2025?

Ans. The Indegene share price target for 2025 was based on FY26 earnings projections. The current 2026 analyst target is Rs 610, reflecting FY27 growth potential from CMP Rs 510.35.

Is Indegene a good buy at Rs 510.35?

Ans. At Rs 510.35, Indegene offers potential upside to the share price target of Rs 610 if FY27 earnings recover as projected. Consult a SEBI registered financial advisor before investing.

What is the 52 week high and low of Indegene?

Ans. The 52 week high of Indegene is Rs 800 and the 52 week low is Rs 420. At CMP Rs 510.35, the stock offers upside potential toward the 12-month share price target of Rs 610.

What are the key risks to the Indegene share price target?

Ans. Key risks include FY27 earnings miss, US tariff-driven FII outflows, competitive pressure among peers in healthcare IT like Syneos Health and IQVIA, and broader market volatility impacting Indian equities in 2026.

What are the catalysts for the Indegene share price target?

Ans. Primary catalysts include FY27 PAT recovery, Healthcare Technology and Life Sciences Services sector tailwinds, RBI rate cut support in 2026, Union Budget 2026-27 policy uplift, and normalisation of FII flows into Indian equities.

How does Indegene compare to its peers?

Ans. Indegene operates in Healthcare Technology and Life Sciences Services alongside peers in healthcare IT like Syneos Health and IQVIA. At CMP Rs 510.35 with MCap Rs 12,756 crore, the company is a potential re-rating candidate toward the share price target of Rs 610 on FY27 earnings delivery.

What is the Indegene share price target for 2027?

Ans. The long-term Indegene share price target for FY27 to FY28 is Rs 740 in the bull case, assuming continued earnings growth, sector re-rating, and sustained FII inflows. Consult a SEBI registered financial advisor for personalised guidance.